SCHEMBL5861652

SCHEMBL5861652

Cc1cc(-c2ccc(C(F)(F)F)cn2)sc1C=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.39
NPSR1 Q6W5P4 3/20 0.39
KIF11 P52732 1/20 0.36
PDE2A O00408 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
ALOX5AP P20292 1/20 0.35
FEN1 P39748 1/20 0.35
CYP1A2 P05177 2/20 0.35
CYP2B6 P20813 1/20 0.35
PIK3CD O00329 1/20 0.34
ABL1 P00519 1/20 0.34
EGFR P00533 1/20 0.34
HCK P08631 1/20 0.34
SRC P12931 1/20 0.34
KDR P35968 1/20 0.34
PIK3CA P42336 1/20 0.34
PIK3CB P42338 1/20 0.34
MTOR P42345 1/20 0.34
PIK3CG P48736 1/20 0.34
EPHB4 P54760 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2170776 0.79 PIK3CD (0.36) KDM4ECYP1A2PIK3CDABL1EGFR
SCHEMBL3112824 0.79 JAK2 (0.39) KIF11MAPTALDH1A1SMN1; SMN2GAA
SCHEMBL5861197 0.76 CYP1A2 (0.41) KDM4ENPSR1KIF11PDE2AL3MBTL1
SCHEMBL12408993 0.75 NPSR1 (0.44) KDM4ENPSR1KIF11L3MBTL1CYP1A2
SCHEMBL2173283 0.73 KDM4E (0.50) KDM4ECYP1A2PIK3CDABL1EGFR
SCHEMBL23416964 0.70 CYP1A2 (0.43) KDM4ENPSR1KIF11PDE2AL3MBTL1
SCHEMBL16399380 0.70 HTR2B (0.44) KDM4ENPSR1KIF11PDE2AL3MBTL1
SCHEMBL12215859 0.70 PIK3CD (0.41) KDM4EPIK3CDABL1EGFRHCK
SCHEMBL31595845 0.69 ALDH1A1 (0.41) KDM4ENPSR1KIF11PDE2AL3MBTL1
SCHEMBL18003550 0.69 KIF11 (0.42) KDM4ENPSR1KIF11PDE2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7091237-B2 Furan and thiophene derivatives that activate human peroxisome proliferator activated receptors SMITHKLINE BEECHAM CORPORATION (US) 2006-08-15 US disclosed
EP-1392674-B1 FURAN AND THIOPHENE DERIVATIVES THAT ACTIVATE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS SMITHKLINE BEECHAM CORP (US) 2005-08-10 EP disclosed
US-20040157890-A1 Furan and thiophene derivatives that activate human peroxisome profilerator activated receptors GLAXO GROUP LIMITED (GB) 2004-08-12 US disclosed
CN-1507442-A Furan and thiophene derivatives that activate human peroxisome proliferator activated receptors 2004-06-23 CN disclosed
EP-1392674-A1 FURAN AND THIOPHENE DERIVATIVES THAT ACTIVATE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS GLAXO GROUP LIMITED (GB) 2004-03-03 EP disclosed
WO-2002092590-A1 FURAN AND THIOPHENE DERIVATIVES THAT ACTIVATE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS GLAXO GROUP LIMITED (GB) 2002-11-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157890-A1 Furan and thiophene derivatives that activate human peroxisome profilerator activated receptors PPARG, PPARD, PPARA KDM4E 4485/4885NPSR1 422/4885KIF11 4320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.